Oncolytic Herpes Simplex Virus Type 1 and Host Immune Responses

2007 ◽  
Vol 7 (2) ◽  
pp. 149-155 ◽  
Author(s):  
Hiroshi Fukuhara ◽  
Tomoki Todo
Viruses ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1200
Author(s):  
Ifeanyi Kingsley Uche ◽  
Konstantin G. Kousoulas ◽  
Paul J. F. Rider

The development of cancer causes disruption of anti-tumor immunity required for surveillance and elimination of tumor cells. Immunotherapeutic strategies aim for the restoration or establishment of these anti-tumor immune responses. Cancer immunotherapies include immune checkpoint inhibitors (ICIs), adoptive cellular therapy (ACT), cancer vaccines, and oncolytic virotherapy (OVT). The clinical success of some of these immunotherapeutic modalities, including herpes simplex virus type-1 derived OVT, resulted in Food and Drug Administration (FDA) approval for use in treatment of human cancers. However, a significant proportion of patients do not respond or benefit equally from these immunotherapies. The creation of an immunosuppressive tumor microenvironment (TME) represents an important barrier preventing success of many immunotherapeutic approaches. Mechanisms of immunosuppression in the TME are a major area of current research. In this review, we discuss how oncolytic HSV affects the tumor microenvironment to promote anti-tumor immune responses. Where possible we focus on oncolytic HSV strains for which clinical data is available, and discuss how these viruses alter the vasculature, extracellular matrix and immune responses in the tumor microenvironment.


Vaccine ◽  
1993 ◽  
Vol 11 (6) ◽  
pp. 629-636 ◽  
Author(s):  
Masatoshi Hazama ◽  
Aki Mayumi-Aono ◽  
Naoki Asakawa ◽  
Shun'ichi Kuroda ◽  
Shuji Hinuma ◽  
...  

2010 ◽  
Vol 183 (4S) ◽  
Author(s):  
Hiroshi Fukuhara ◽  
Jiangang Hou ◽  
Yuzuri Tsurumaki ◽  
Yukio Homma ◽  
Yasushi Ino ◽  
...  

2008 ◽  
Vol 14 (5) ◽  
pp. 1571-1580 ◽  
Author(s):  
Peter C. Huszthy ◽  
Dorota Goplen ◽  
Frits Thorsen ◽  
Heike Immervoll ◽  
Jian Wang ◽  
...  

2010 ◽  
Vol 12 (7) ◽  
pp. 613-623 ◽  
Author(s):  
Arturo R. Maldonado ◽  
Chuck Klanke ◽  
Anil G. Jegga ◽  
Bruce J. Aronow ◽  
Yonatan Y. Mahller ◽  
...  

Blood ◽  
2011 ◽  
Vol 118 (1) ◽  
pp. 107-115 ◽  
Author(s):  
Alexandros A. Theodoridis ◽  
Christina Eich ◽  
Carl G. Figdor ◽  
Alexander Steinkasserer

Abstract Immune responses require spatial and temporal coordinated interactions between different cell types within distinct microenvironments. This dynamic interplay depends on the competency of the involved cells, predominantly leukocytes, to actively migrate to defined sites of cellular encounters in various tissues. Because of their unique capacity to transport antigen from the periphery to secondary lymphoid tissues for the activation of naive T cells, dendritic cells (DCs) play a key role in the initiation and orchestration of adaptive immune responses. Therefore, pathogen-mediated interference with this process is a very effective way of immune evasion. CYTIP (cytohesin-interacting protein) is a key regulator of DC motility. It has previously been described to control LFA-1 deactivation and to regulate DC adherence. CYTIP expression is up-regulated during DC maturation, enabling their transition from the sessile to the motile state. Here, we demonstrate that on infection of human monocyte-derived DCs with herpes simplex virus type 1 (HSV-1), CYTIP is rapidly degraded and as a consequence β-2 integrins, predominantly LFA-1, are activated. Furthermore, we show that the impairment of migration in HSV-1-infected DCs is in part the result of this increased integrin-mediated adhesion. Thus, we propose a new mechanism of pathogen-interference with central aspects of leukocyte biology.


Sign in / Sign up

Export Citation Format

Share Document